op-3136
·Code: OP-3136
op-3136: sourced relationships with 1 company · 1 clinical trial tracked.
op-3136 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect op-3136 to OLMA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could op-3136 → OLMA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Metastatic Breast Cancer
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors
Primary endpoint: Number of participants with dose-limiting toxicities in the Dose Escalation Arms
InterventionalRandomizedopen180 targetStarted 2024-12Completion 2027-0825 sites · Australia, France, Hong Kong, Ireland…Olema Pharmaceuticals, Inc.
Frequently asked questions
Which companies have sourced relationships with op-3136?
op-3136 has dated SEC/FDA relationship records for Olema Pharmaceuticals, Inc..
How many clinical trials involve op-3136?
BioSniper tracks 1 clinical trial involving op-3136.